Supernus Pharma (SUPN) Tops Q2 EPS by 3c, Revenues Miss; Offers Revised FY19 Revenues Guidance Below Consensus

August 6, 2019 4:56 PM

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.61, $0.03 better than the analyst estimate of $0.58. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found